Baidu
map

Lancet子刊:小气道疾病与哮喘结局显著相关,ATLANTIS前瞻性队列研究数据给出答案

2022-03-26 小文子 MedSci原创

为了更好的治疗哮喘患者,应评估小气道功能、大气道功能和生物标记物,作为哮喘表型的一部分,以更好地了解患者预后不良的风险。

全世界哮喘患者超过3亿,哮喘是一种影响患者整个支气管的阻塞性气道疾病。ATLANTIS研究结合了生物标志物、生理测试和影像学,更好地评估哮喘患者小气道疾病的存在和严重程度。Lancet Respir Med杂志的一项研究根据ATLANTIS随访1年的数据评估了哪些小气道参数与哮喘控制、病情恶化和生活质量密切相关。

2014年6月30日至2017年3月3日期间,通过9个国家的医学数据库招募轻度、中度和重度稳定期哮喘患者。要求参与者年龄18-65岁,确诊哮喘至少6个月。对参与者随访1年,分别在基线、6个月和12个月时随访。生理测试包括肺活量测定、肺容积、脉冲振荡法、多次呼气氮冲洗试验(MBNW)和乙酰胆碱激发期间用力肺活量下降百分比。CT强化扫描评估小气道疾病。评估测量值与哮喘恶化、哮喘控制和生活质量之间的关系。构建复合有序评分,包括脉冲震荡参数R5-20(中小气道电阻)、AX(电抗面积)和X5(更中心,传导频率5Hz的小气道电抗)。

研究最后纳入773名参与者(中位年龄46岁[IQR 34–54];450名[58%]女性)。单变量分析显示,脉冲振荡法、肺容量、MBNW和FEF 25%-75%与哮喘控制和哮喘急性加重相关(ρ=0.20-0.25,p<0.0001)。脉冲振荡序列评分增加与队列中病情恶化增加直接相关。随着序列评分的增加,表明小气道阻力增加,病情恶化的次数也增加。脉冲振荡测量单独和整体地与哮喘的纵向加重相关,序列评分有助于模型预测恶化的能力。序列得分增加1分相当于病情恶化率增加16%。而CT参数与哮喘控制、急性加重和生活质量无相关性。

结果表明,通过R5-20、AX和X5脉冲振荡法可以轻松测量小气道疾病,预测哮喘的控制和恶化。为了更好的治疗哮喘患者,应评估小气道功能、大气道功能和生物标记物,作为哮喘表型的一部分,以更好地了解患者预后不良的风险。

 

原文出处:

Monica Kraft, Matthew Richardson, et al, The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study, Lancet Respir Med 2022, https://doi.org/10.1016/S2213-2600(21)00536-1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-24 qidongfanjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-08-02 howi
  7. [GetPortalCommentsPageByObjectIdResponse(id=1950261, encodeId=1777195026108, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sun Apr 24 07:02:39 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989266, encodeId=a06319892661b, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Aug 13 10:02:39 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937647, encodeId=eea4193e64775, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Mon Jan 16 00:02:39 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954338, encodeId=9ffd1954338b6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 24 11:02:39 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006562, encodeId=24d4200656277, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 12 19:02:39 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831513, encodeId=5925183151339, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 02 21:02:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208639, encodeId=e10b1208639eb, content=哦可, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Mon Apr 04 21:18:04 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-04 13a65af0m37暂无昵称

    哦可

    0

相关资讯

Adv Ther:社会因素对哮喘和湿疹的影响

哮喘和特应性皮炎(湿疹)是密切相关的,而且通常是伴发的,而社会因素如收入水平、文化差异等是否也会影响到其治疗和发病,该文对这一问题进行了研究。

JACIP:Dupilumab单抗显示对特应性皮炎、哮喘、鼻窦炎并鼻息肉的快速反应

Dupilumab被批准用于治疗某些中到重度特应性皮炎(AD)、中到重度哮喘和慢性鼻-鼻窦炎并鼻息肉患者。本文评估了139名患者在接受dupilumab治疗中症状和临床相关结果有意义的变化。

Radiology:让我们通过3He MRI重新认识CT上发现的粘液栓!

通气异质性是哮喘的基础病理生理特征,可通过超极化氦3(3He)MRI观察到的通气障碍反映。

不敢用药,怀孕的哮喘患者怎么办?

30岁女性,目前怀孕13周。最近1个月哮喘反复发作,自己能听到夜间有喘鸣声,有时胸口闷,像有东西压住,需要坐起来用力呼吸,白天好转,能比较正常活动,有时咳嗽,干咳无痰,晚上多一些。

NEJM:患者自主激素吸入方案可降低中重度哮喘患者恶化风险

在患有中度至重度哮喘的黑人和拉丁裔成年人中,在常规治疗基础上,提供吸入糖皮质激素和一次专业的使用指导,可降低严重哮喘发作率,改善患者预后

PAL:持续性哮喘患者在儿童早期即出现肺功能受损

女性、接受ICS治疗和频繁哮喘急性加重是儿童持续性哮喘的危险因素。

Baidu
map
Baidu
map
Baidu
map